EUR 0.02
(-4.17%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -709 Thousand EUR | 87.29% |
2022 | -5.57 Million EUR | -2214.11% |
2021 | -241 Thousand EUR | 82.31% |
2020 | -1.36 Million EUR | 91.3% |
2019 | -15.65 Million EUR | -9.32% |
2018 | -14.32 Million EUR | -19.48% |
2017 | -11.98 Million EUR | 2.86% |
2016 | -12.33 Million EUR | -59.94% |
2015 | -7.71 Million EUR | -74.19% |
2014 | -4.42 Million EUR | -90.99% |
2013 | -2.31 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2023 Q2 | 725 Thousand EUR | 146.24% |
2023 FY | -709 Thousand EUR | 87.29% |
2023 Q4 | -1.43 Million EUR | -297.79% |
2022 Q4 | -1.56 Million EUR | 60.89% |
2022 FY | -5.57 Million EUR | -2214.11% |
2022 Q2 | -4 Million EUR | -200.33% |
2021 FY | -241 Thousand EUR | 82.31% |
2021 Q4 | 3.99 Million EUR | 4056.44% |
2021 Q2 | -101 Thousand EUR | -129.55% |
2020 Q2 | -1.31 Million EUR | 83.17% |
2020 FY | -1.36 Million EUR | 91.3% |
2020 Q4 | -44 Thousand EUR | 96.66% |
2019 Q4 | -7.83 Million EUR | -0.1% |
2019 FY | -15.65 Million EUR | -9.32% |
2019 Q2 | -7.82 Million EUR | 12.55% |
2018 Q4 | -8.94 Million EUR | -66.49% |
2018 FY | -14.32 Million EUR | -19.48% |
2018 Q2 | -5.37 Million EUR | -4.07% |
2017 Q2 | -6.82 Million EUR | -40.43% |
2017 Q4 | -5.16 Million EUR | 24.3% |
2017 FY | -11.98 Million EUR | 2.86% |
2016 Q2 | -7.48 Million EUR | -65.22% |
2016 FY | -12.33 Million EUR | -59.94% |
2016 Q4 | -4.85 Million EUR | 35.06% |
2015 Q2 | -3.18 Million EUR | 0.0% |
2015 Q4 | -4.52 Million EUR | -42.08% |
2015 FY | -7.71 Million EUR | -74.19% |
2014 FY | -4.42 Million EUR | -90.99% |
2013 FY | -2.31 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Nicox S.A. | -20.88 Million EUR | 96.605% |
FERMENTALG | -14.14 Million EUR | 94.989% |
PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 96.981% |